 Erin Stenson
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 11 | 2026 | 874 | 2.670 |
Why?
| | Shock, Septic | 4 | 2023 | 227 | 1.710 |
Why?
| | Water-Electrolyte Imbalance | 3 | 2018 | 42 | 1.190 |
Why?
| | Critical Illness | 6 | 2026 | 900 | 1.120 |
Why?
| | Chlorides | 2 | 2018 | 138 | 1.030 |
Why?
| | Sepsis | 4 | 2024 | 664 | 0.800 |
Why?
| | Hemodiafiltration | 1 | 2022 | 7 | 0.720 |
Why?
| | Complement Factor B | 1 | 2023 | 106 | 0.720 |
Why?
| | Sodium | 1 | 2022 | 198 | 0.690 |
Why?
| | Renal Dialysis | 2 | 2024 | 466 | 0.660 |
Why?
| | Hypotension | 1 | 2022 | 127 | 0.650 |
Why?
| | Acidosis | 1 | 2021 | 105 | 0.630 |
Why?
| | Complement System Proteins | 1 | 2022 | 314 | 0.590 |
Why?
| | Child | 20 | 2026 | 22740 | 0.570 |
Why?
| | Kidney Diseases | 1 | 2022 | 426 | 0.550 |
Why?
| | Kidney | 3 | 2024 | 1497 | 0.540 |
Why?
| | Vena Cava, Inferior | 1 | 2018 | 83 | 0.510 |
Why?
| | Drug Overdose | 1 | 2022 | 375 | 0.510 |
Why?
| | Research Design | 1 | 2022 | 1139 | 0.480 |
Why?
| | Registries | 1 | 2024 | 2410 | 0.430 |
Why?
| | Aorta | 1 | 2018 | 440 | 0.430 |
Why?
| | Echocardiography | 1 | 2018 | 648 | 0.430 |
Why?
| | Infant | 11 | 2026 | 10091 | 0.420 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1154 | 0.400 |
Why?
| | Prospective Studies | 8 | 2026 | 8078 | 0.370 |
Why?
| | Renal Replacement Therapy | 4 | 2026 | 100 | 0.350 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2023 | 288 | 0.300 |
Why?
| | Complement Activation | 2 | 2022 | 399 | 0.290 |
Why?
| | Child, Preschool | 10 | 2026 | 11868 | 0.280 |
Why?
| | Humans | 25 | 2026 | 145783 | 0.270 |
Why?
| | Bacterial Infections | 2 | 2019 | 247 | 0.240 |
Why?
| | Retrospective Studies | 9 | 2026 | 17330 | 0.240 |
Why?
| | Multiple Organ Failure | 1 | 2026 | 120 | 0.230 |
Why?
| | Asthma | 1 | 2017 | 1797 | 0.220 |
Why?
| | Sister Chromatid Exchange | 1 | 2004 | 4 | 0.220 |
Why?
| | Trinucleotide Repeats | 1 | 2004 | 31 | 0.210 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2004 | 117 | 0.210 |
Why?
| | Vasopressins | 1 | 2024 | 61 | 0.210 |
Why?
| | Intensive Care Units | 2 | 2021 | 924 | 0.200 |
Why?
| | Vasoconstrictor Agents | 1 | 2024 | 150 | 0.200 |
Why?
| | Biomarkers | 5 | 2023 | 4302 | 0.200 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 148 | 0.190 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 37 | 0.190 |
Why?
| | Female | 13 | 2026 | 79045 | 0.190 |
Why?
| | Male | 15 | 2026 | 73010 | 0.190 |
Why?
| | Adolescent | 9 | 2026 | 22577 | 0.180 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2022 | 21 | 0.180 |
Why?
| | Toxicokinetics | 1 | 2022 | 8 | 0.180 |
Why?
| | Potassium | 1 | 2022 | 152 | 0.180 |
Why?
| | Valproic Acid | 1 | 2022 | 49 | 0.180 |
Why?
| | Benzodiazepines | 1 | 2022 | 168 | 0.170 |
Why?
| | Fruit | 1 | 2021 | 146 | 0.160 |
Why?
| | Immunocompromised Host | 2 | 2019 | 202 | 0.160 |
Why?
| | Saccharomyces cerevisiae | 1 | 2004 | 574 | 0.150 |
Why?
| | Eating | 1 | 2022 | 387 | 0.150 |
Why?
| | PPAR alpha | 1 | 2019 | 55 | 0.150 |
Why?
| | Nephritis | 1 | 2019 | 22 | 0.150 |
Why?
| | Interleukin-27 | 1 | 2018 | 13 | 0.140 |
Why?
| | Logistic Models | 1 | 2024 | 2139 | 0.140 |
Why?
| | Infant, Newborn | 3 | 2024 | 6465 | 0.130 |
Why?
| | Wounds and Injuries | 1 | 2026 | 962 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2024 | 668 | 0.130 |
Why?
| | Organ Size | 1 | 2018 | 461 | 0.120 |
Why?
| | Pain | 1 | 2022 | 791 | 0.120 |
Why?
| | Reference Values | 1 | 2018 | 798 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2019 | 507 | 0.120 |
Why?
| | Cognition | 1 | 2024 | 1271 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2026 | 1925 | 0.110 |
Why?
| | Anti-Asthmatic Agents | 1 | 2017 | 260 | 0.110 |
Why?
| | Acute Disease | 1 | 2017 | 1036 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1271 | 0.100 |
Why?
| | Quality Improvement | 2 | 2026 | 1296 | 0.100 |
Why?
| | Young Adult | 3 | 2024 | 14254 | 0.090 |
Why?
| | Energy Metabolism | 1 | 2019 | 935 | 0.090 |
Why?
| | Databases, Factual | 1 | 2018 | 1491 | 0.090 |
Why?
| | Prognosis | 2 | 2018 | 4330 | 0.090 |
Why?
| | Models, Biological | 1 | 2019 | 1764 | 0.080 |
Why?
| | Critical Care | 1 | 2017 | 702 | 0.080 |
Why?
| | Quality of Life | 1 | 2023 | 3211 | 0.080 |
Why?
| | Chromosomes | 1 | 2010 | 106 | 0.080 |
Why?
| | Embryonic Development | 1 | 2010 | 125 | 0.080 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 410 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2010 | 507 | 0.070 |
Why?
| | Disease Progression | 1 | 2017 | 2865 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2024 | 11794 | 0.070 |
Why?
| | Risk Factors | 2 | 2026 | 10919 | 0.070 |
Why?
| | Databases, Nucleic Acid | 1 | 2008 | 38 | 0.070 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2008 | 90 | 0.060 |
Why?
| | Hospitalization | 1 | 2017 | 2461 | 0.060 |
Why?
| | RNA, Untranslated | 1 | 2008 | 121 | 0.060 |
Why?
| | Abbreviated Injury Scale | 1 | 2026 | 28 | 0.060 |
Why?
| | Rad52 DNA Repair and Recombination Protein | 1 | 2004 | 1 | 0.050 |
Why?
| | Rad51 Recombinase | 1 | 2004 | 15 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2383 | 0.050 |
Why?
| | United States | 2 | 2024 | 16126 | 0.050 |
Why?
| | Exodeoxyribonucleases | 1 | 2004 | 23 | 0.050 |
Why?
| | Endodeoxyribonucleases | 1 | 2004 | 77 | 0.050 |
Why?
| | Adult | 2 | 2024 | 40881 | 0.050 |
Why?
| | Injury Severity Score | 1 | 2026 | 599 | 0.050 |
Why?
| | Cohort Studies | 2 | 2024 | 6033 | 0.050 |
Why?
| | Computational Biology | 1 | 2008 | 669 | 0.050 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2004 | 414 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3752 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 4090 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1137 | 0.040 |
Why?
| | Incidence | 1 | 2026 | 2934 | 0.040 |
Why?
| | Area Under Curve | 1 | 2018 | 332 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 468 | 0.030 |
Why?
| | DNA | 1 | 2004 | 1437 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2018 | 298 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1482 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 618 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 672 | 0.030 |
Why?
| | Recovery of Function | 1 | 2020 | 716 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5992 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 2000 | 0.020 |
Why?
| | Survival Rate | 1 | 2018 | 2094 | 0.020 |
Why?
| | Mice | 1 | 2010 | 18355 | 0.020 |
Why?
| | Bacteria | 1 | 2018 | 766 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2933 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3130 | 0.020 |
Why?
| | Ethylnitrosourea | 1 | 2010 | 13 | 0.020 |
Why?
| | Genes, Lethal | 1 | 2010 | 30 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2010 | 72 | 0.020 |
Why?
| | Spermatogenesis | 1 | 2010 | 91 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2010 | 191 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2601 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 2010 | 538 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5428 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4568 | 0.020 |
Why?
| | New York | 1 | 2008 | 128 | 0.020 |
Why?
| | Animals | 3 | 2019 | 38101 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5224 | 0.010 |
Why?
| | Internet | 1 | 2008 | 693 | 0.010 |
Why?
| | Artificial Intelligence | 1 | 2008 | 381 | 0.010 |
Why?
| | Software | 1 | 2008 | 680 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1851 | 0.010 |
Why?
|
|
Stenson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|